Biotech Stocks 2016 – Below is a list of my top biotech stocks for 2016. Biotech Stocks are very volatile because companies are constantly releasing drug data which could make or break the company. Finding the best biotech stocks is not an easy task. The top biotech stocks to buy are probably biotech stocks that have missed a key trial but will eventually rebound. Less risky biotech stocks are probably your best option because they likely already have a good drug or two and have solid earnings. I will highlight the top biotech stocks to watch right now but do your own research and understand that these biotech stock picks can rise or tank with one piece of news.
Top Biotech Stocks 2016 – Stocks to Buy – Biotech Stocks – Bluebird bio (BLUE) – The best drug stock to buy in 2016 is still Bluebird bio (BLUE). Bluebird bio, Inc. (BLUE) is back trading in the $50’s after recently hitting $100. BlueBird’s Beta-thalassemia drug Lentiglobin, replaces the defective gene with one that is fully functional. It’s a one-time treatment with the goal of freeing patients from requiring chronic blood transfusions, or reducing the volume of blood transfusions. BLUE will be a top biotechnology stock in 2016 and I’m expecting shares to again rally up to $80. but expect a lot of volatility.
Bluebird bio (BLUE), a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic and rare diseases. Its advanced product candidate is Lenti-D, which is in phase II/III clinical studies for the treatment of childhood cerebral adrenoleukodystrophy, a rare, hereditary neurological disorder affecting young boys; and LentiGlobin that is in phase I/II clinical studies for the treatment of beta-thalassemia major and severe sickle cell disease (SCD) in France, as well as a phase I study in the United States for the treatment of severe SCD. The company also develops various CAR T cell products for liquid and solid tumor cancers. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; and a collaboration with Seattle Children’s Research Institute to develop transformative gene therapies for various inherited blood diseases, including bubble boy disease, SCD, and immune deficiency or marrow failure syndromes
Biotech Stocks to Buy 2016 – Intrexon (XON) – Intrexon (XON) is trading at $31.50 and is one of the Top Biotech Stocks for 2016. Intrexon operates in the synthetic biology field through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Bill Miller has called XON the Netflix (NFLX) of the biotechnology sector and we could see massive gains in the next 5-10 years the company delivers. Intrexon (XON) is a good stock pick for 2016 and I have a $50 price target.
Biotech Stocks to Watch 2016
Intra-Cellular Therapies, Inc. (ITCI)
GW Pharmaceuticals plc (GWPH)
Clovis Oncology, Inc. (CLVS)
KaloBios Pharmaceuticals, Inc. (KBIO)